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LETTERS
HLA class II allele polymorphism in Hungarian patients with
primary Sjo¨gren’s syndrome
A Kova´cs1, E Endreffy2, I Petri3, L Kova´cs1, G Pokorny1
Departments of 1Rheumatology, 2Paediatrics and 3Transfusiology, University of Szeged, Albert Szent-Gyo¨rgyi Medical and Pharmaceutical
Centre and City Hospital, Szeged, Hungary
Previous data suggest that human leucocyte antigen
(HLA) class II allele polymorphisms are involved in
the development of primary Sjo¨gren’s syndrome
(pSS). HLA DR3, DR2, and DR5 (DRB1*03, *15/16,
*11/12) have been found with elevated frequency
in pSS and the DR3 positivity correlates with the
anti-Ro(SSA) and anti-La(SSB) autoantibody posi-
tivities and extraglandular manifestations (1, 2). In
Greek pSS patients, the incidence of the DR5 allele
was significantly increased, whereas no differences
in HLA were found between anti-Ro(SSA)-positive
and -negative SS patients (3). Finnish pSS patients
with the HLA-DRB1*0301-DQA1*0501-DQB1*0201
haplotypes were observed to have significantly higher
anti-SSA/Ro and anti-SSB/La antibody levels than
did the patients without this haplotype (4). This
autoantibody response likewise associated positively
with DRB1*03-DQB1*02 and DRB1*03/DRB1*15-
DQB1*02/DQB1*0602 heterozygosity in a German
population (5). In French patients (6), the HLA
alleles predisposed to autoantibody secretion without
being associated with a clinical outcome (DRB1*15
favoured anti-SSA, and DRB1*03 both anti-SSA and
anti-SSB production). In Norwegian pSS patients,
similar HLA allele findings (DRB1*0301 and
DRB3*0101 alleles) were reported, and these alleles
were more closely associated with the presence of
anti-Ro autoantibodies than with pSS itself (7).
Our aim was to determine the HLA class II allele
polymorphisms, and to analyse the pheno- and
genotype correlations in 48 Hungarian pSS patients,
who all fulfilled the classification criteria for pSS
syndrome (8). Forty-seven females and one male,
with a mean age at the time of the examination of 55
years (range 33–83), and 50 healthy blood donors
matched for age and sex as controls were studied.
HLA-DRB1 was genotyped with the Dynal RELI
SSO HLA-DRB kit, DRB1*15/16 was subtyped with
the method of Ota et al (9), DQA1 by the method of
Ota et al (10), and DQB1 with the INNO-LiPA DQB
kit (Norway). A x2-test with Yates’ and Bonferroni’s
corrections was performed, and odds ratios (ORs)
were also calculated.
In the pSS patients, DRB1*03-DQA1*05011-
DQB1*0201 proved to be the haplotype of suscept-
ibility, even when Bonferroni’s correction was used
(p(0.01, Table 1). The DRB1*1601 (OR 3.5) and
DQA1*0102 (OR 2.5) alleles also occurred more
frequently (p(0.05), compared with the controls. By
contrast, the DRB1*01-DQA1*0101-DQB1*0501,
DRB1*04-DQA1*0301-DQB1*0302 and DRB1*11/
12-DQA1*05012-DQB1*0301 haplotypes were less
common in the pSS patients (pv0.05 and pv0.02,
respectively, Table 1). However, after the use of
Bonferroni’s correction, the difference did not remain
significant.
We analysed the HLA class II alleles in the SS
subgroups separated according to the anti-SSA/anti-
SSB seropositivity and to seronegativity. In the 20
anti-SSB-positive pSS patients, the DRB1*03 allele
frequency was significantly higher than in the 28 anti-
SSB negative cases (17/40 vs. 12/56, pv0.05), but
there was no similar difference between the patients
with anti-SSA positivity or anti-SSA negativity
(22/66 vs. 6/30, ns). By contrast, the DRB1*15/16
(DR2) alleles were detected significantly more
frequently in the anti-SSB-negative than in the anti-
SSB-positive patients (18/56 vs. 3/40, pv0.05), and in
the anti-SSA plus anti-SSB-negative patients com-
pared with the anti-SSA plus anti-SSB-positive
patients (8/24 vs. 4/34, p50.02).
The DRB1*03 allele was more common in nine pSS
patients who exhibited purpura than in those without
this vascular manifestation (9/18 vs. 21/78, ns). By
contrast, the DRB1*15/16 alleles were less frequent in
the patients with purpura (2/18 vs. 21/78, ns). Eleven
pSS patients developed renal tubular acidosis, and
DRB1*03 proved to be an allele of susceptibility
(12/22 vs. 18/74, pv0.02), and DRB1*11/12 one of
resistance (0/22 vs. 11/74, pv0.05) as compared with
the patients without kidney involvement. Malignant
lymphomas developed in five pSS patients (Hodgkin
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in one and non-Hodgkin in four); all of them carried
the DRB1*03 allele (6/10 vs. 24/86 alleles, pv0.05,
Yates’s correction; ns).
To summarize, in 48 Hungarian pSS patients,
DRB1*0301-DQA1*05011-DQB1*0201 proved to be
the haplotype of susceptibility. The DRB1*03 allele
exhibited a positive correlation with anti-SSB auto-
antibody production, the presence of renal tubular
acidosis, and the development of malignant lym-
phoma. The DRB1*15/16 (DR2) alleles were
detected more frequently in the anti-SSB-negative
patients than in the anti-SSB-positive patients, and in
the anti-SSA plus anti-SSB-negative patients than in
the anti-SSA plus anti-SSB-positive patients. Our
results suggest a model of HLA-restricted presenta-
tion of Ro/La peptide determinants in pSS.
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